Skip to main content
Clinical Trials/NCT00750633
NCT00750633
Completed
Phase 3

A Phase III Study of an Otic Formulation in Acute Otitis Externa

Alcon Research0 sites990 target enrollmentJune 2008

Overview

Phase
Phase 3
Intervention
Moxidex otic solution
Conditions
Acute Otitis Externa
Sponsor
Alcon Research
Enrollment
990
Primary Endpoint
Clinical Cure
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to determine if an otic formulation is safe and effective for the treatment of acute otitis externa (AOE).

Registry
clinicaltrials.gov
Start Date
June 2008
End Date
January 2009
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of AOE based on clinical observation and of presumed bacterial origin
  • A minimum combined score of ≥4 in at least 1 affected ear at the Day 1 exam for tenderness, erythema, and edema
  • Other protocol-defined inclusion criteria may apply

Exclusion Criteria

  • Duration of pretherapy signs or symptoms of AOE greater than four (4) weeks
  • Presence of a tympanostomy tube or perforated tympanic membrane in the treated ear(s). Patients with a history of tympanic membrane perforation should not be enrolled unless the absence of a current perforation can be confirmed at Visit 1 prior to enrollment
  • Clinically diagnosed chronic suppurative otitis media, acute otitis media, acute otorrhea in patients with tympanostomy tubes, or malignant otitis externa
  • Known or suspected ear infection of fungal or mycobacterial origin
  • Prior otologic surgery within 6 months of study entry
  • Seborrheic dermatitis or other skin conditions of the external auditory canal
  • Current or prior history of an immunosuppressive disorder (e.g., HIV positive) or current immunosuppressive therapy (e.g., cancer chemotherapy) or known acute or chronic renal disorders or active hepatitis
  • Diabetic patients (controlled or uncontrolled) based upon assessment by Investigator
  • Any systemic disease or disorder, complicating factor or structural abnormality that would negatively affect the conduct or outcome of the study \[e.g., cleft palate (including repairs), Downs Syndrome, and cranial facial reconstruction\]
  • Any current known or suspected infection (other than AOE) requiring systemic antimicrobial therapy

Arms & Interventions

Moxidex

Moxidex otic solution

Intervention: Moxidex otic solution

Moxidex

Moxidex otic solution

Intervention: Tympanostomy tubes

Moxifloxacin

Moxifloxacin otic solution

Intervention: Moxifloxacin otic solution

Moxifloxacin

Moxifloxacin otic solution

Intervention: Tympanostomy tubes

Dexamethasone

Dexamethasone phosphate otic solution

Intervention: Dexamethasone phosphate otic solution

Dexamethasone

Dexamethasone phosphate otic solution

Intervention: Tympanostomy tubes

Outcomes

Primary Outcomes

Clinical Cure

Time Frame: Day 12

Secondary Outcomes

  • Microbiological Success(Day 12)

Similar Trials